Mesoporous silica nanomaterials (MSNs) have made remarkable achievements and are being thought of by researchers as materials that can be used to effect great change in cancer therapies, gene delivery, and drug delivery because of their optically transparent properties, flexible size, functional surface, low toxicity profile, and very good drug loading competence. Mesoporous silica nanoparticles (MSNPs) show a very high loading capacity for therapeutic agents. It is well known that cancer is one of the most severe known medical conditions, characterized by cells that grow and spread rapidly. Thus, curtailing cancer is one of the greatest current challenges for scientists. Nanotechnology is an evolving field of study, encompassing medicine, engineering, and science, and it has evolved over the years with respect to cancer therapy. This review outlines the applications of mesoporous nanomaterials in the field of cancer theranostics, as well as drug and gene delivery. MSNs employed as therapeutic agents, as well as their importance and future prospects in the ensuing generation of cancer theranostics and drug and therapeutic gene delivery, are discussed herein. Thus, the use of mesoporous silica nanomaterials can be seen as using one stone to kill three birds.

Background: The timely prediction in the risk of Hospital-Acquired Pneumonia（HAP）in Acute Ischemic stroke (AIS) patients after Mechanical thrombectomy (MT) treatment is of high priority, given the rise in AIS mortality as a result. Although prior extensive research has been conducted in HAP preventive management and therapeutics, ischemic stroke patients are still at serious risk of contracting In-hospital pneumonia infections following certain medical procedures like Mechanical thrombectomy, a care standard for AIS patients. The predictive accuracy of patients with higher infection risk and adjusting therapeutic strategies accordingly will not only provide an enhanced preventive measure perspective but also significantly improve patient outcomes. Hence, our study was aimed at the validation and development of a novel predictive tool for risk stratification and individualized predictions of HAP occurrence in AIS patients after MT therapy. Method: A multicenter retrospective study was executed with 405 AIS patients after undergoing MT treatment and admitted to the three Chinese stroke units. The major measure of outcome was to estimate the risk of HAP after MT through the integration of the following four predictors FBG, Age, NHISS, and Diastolic blood pressure (FAND) into a nomogram. Assessed on the multivariate logistic model, a nomogram was constructed, using the area under the receiver-operating characteristic curve to evaluate the discriminative performance and the Hosmer–Lemeshow test for risk prediction model calibration. Results: Age(OR:1039; 95%Cl 1.017-1.062; p=0.001), NIHSS(National Institutes of Health Stroke Scale) score on admission(OR:1.066; 95%Cl: 1.030-1.103); p< 0.0001), diastolic blood pressure(OR 1.023; 95% Cl 1.006-1.040: p=0.008), Fasting blood glucose(OR 1.1444; 95% Cl 1.029-1.271; p=0.013) remained independent predictors of HAP integrated into the FAND nomogram after AIS Chinese patients received MT treatment. The Hosmer-Lemeshow goodness-of fit-test expressed good calibration(p-value: 0.496) and Area under the curve of 0.737 was exhibited for functional impairment prediction. Conclusion: The FAND nomogram is a novel prognostic model developed and validated in Chinese AIS patients after MT treatment may aid in preventive measure strategies and predict poor patient outcomes.